Sauder J M, Arthur J W, Dunbrack R L
Fox Chase Cancer Center, Institute for Cancer Research, 7701 Burholme Avenue, Philadelphia, PA 19111, USA.
J Mol Biol. 2000 Jul 7;300(2):241-8. doi: 10.1006/jmbi.2000.3860.
The enzyme BACE (beta-site APP-cleaving enzyme) has recently been identified as the beta-secretase that cleaves the amyloid precursor protein (APP) to produce the N terminus of the Abeta peptide found in plaques in the brains of Alzheimer's disease patients. BACE is an aspartic protease similar to pepsin and renin. Comparative modeling of the three-dimensional structure of BACE in complex with its substrate shows that several residues confer specificity of the enzyme for APP. In particular, Arg296 forms a salt-bridge with the P1' Asp of the APP substrate, explaining the unusual preference of BACE among aspartic proteases for a P1' residue that is negatively charged. Several hydrophobic residues in the enzyme form a pocket for the P1 hydrophobic residue (Met in wild-type APP and Leu in APP with the "Swedish mutation" associated with early-onset of Alzheimer's disease). Inhibitors that can bind to the BACE active site may prove useful for drugs to treat and prevent Alzheimer's disease.
酶BACE(β-位点淀粉样前体蛋白裂解酶)最近被确定为β-分泌酶,它可裂解淀粉样前体蛋白(APP),产生在阿尔茨海默病患者大脑斑块中发现的Aβ肽的N端。BACE是一种与胃蛋白酶和肾素类似的天冬氨酸蛋白酶。BACE与其底物复合物三维结构的比较建模表明,几个残基赋予了该酶对APP的特异性。特别是,Arg296与APP底物的P1' Asp形成盐桥,这解释了BACE在天冬氨酸蛋白酶中对带负电荷的P1' 残基的异常偏好。该酶中的几个疏水残基形成了一个容纳P1疏水残基的口袋(野生型APP中的Met以及与早发性阿尔茨海默病相关的具有“瑞典突变”的APP中的Leu)。能够结合BACE活性位点的抑制剂可能被证明对治疗和预防阿尔茨海默病的药物有用。